Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

ClinicalTrials.gov ID: NCT00064623

Public ClinicalTrials.gov record NCT00064623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is effective in treating painful HIV-associated neuropathy.

Study identification

NCT ID
NCT00064623
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
NeurogesX
Industry
Enrollment
300 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2003 (Type not available)
Primary completion
Not listed
Completion
Nov 2005 (Type not available)
Last update posted
Mar 6, 2008

2003 – 2005

United States locations

U.S. sites
35
U.S. states
18
U.S. cities
32
Facility City State ZIP Site status
NeurogesX Investigational Site Phoenix Arizona 85006 —
NeurogesX Investigational Site Phoenix Arizona 85023 —
NeurogesX Investigational Site Berkeley California 94609 —
NeurogesX Investigational Site San Diego California 92103 —
NeurogesX Investigational Site San Francisco California 94117 —
NeurogesX Investigational Site Stanford California 94305 —
NeurogesX Investigational Site West Hollywood California 90069 —
NeurogesX Investigational Site Fort Lauderdale Florida 33306 —
NeurogesX Investigational Site Miami Florida 33133 —
NeurogesX Investigational Site Miami Florida 33136 —
NeurogesX Investigational Site North Palm Beach Florida 33408 —
NeurogesX Investigational Site Orlando Florida 32804 —
NeurogesX Investigational Site Sunrise Florida 33351 —
NeurogesX Investigational Site Vero Beach Florida 32960 —
NeurogesX Investigational Site Honolulu Hawaii 96816 —
NeurogesX Investigational Site Chicago Illinois 60612 —
NeurogesX Investigational Site Lexington Kentucky 40536 —
NeurogesX Investigational Site Baltimore Maryland 21205 —
NeurogesX Investigational Site Boston Massachusetts 02215 —
NeurogesX Investigational Site Springfield Massachusetts 01107 —
NeurogesX Investigational Site Detroit Michigan 48201 —
NeurogesX Investigational Site Minneapolis Minnesota 55416 —
NeurogesX Investigational Site St Louis Missouri 63108 —
NeurogesX Investigational Site Camden New Jersey 08103-1489 —
NeurogesX Investigational Site Albany New York 12208 —
NeurogesX Investigational Site New York New York 10021 —
NeurogesX Investigational Site New York New York 10029 —
NeurogesX Investigational Site Chapel Hill North Carolina 27599 —
NeurogesX Investigational Site Cleveland Ohio 44106 —
NeurogesX Investigational Site Portland Oregon 97209 —
NeurogesX Investigational Site Austin Texas 78705 —
NeurogesX Investigational Site Dallas Texas 75208 —
NeurogesX Investigational Site Houston Texas 77030 —
NeurogesX Investigational Site San Antonio Texas 78229 —
NeurogesX Investigational Site Madison Wisconsin 53792-5132 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00064623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2008 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00064623 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →